Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANESH A ALAM

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1043227200
CMS profile
1133215
Location
WINFIELD, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$17,495.83

24 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $14,730.00 3
Travel and Lodging $1,878.16 6
Food and Beverage $887.67 15

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Alkermes, Inc. $7,500.00 1
US WorldMeds, LLC $5,144.56 11
Janssen Pharmaceuticals, Inc $4,351.45 8
LivaNova USA, Inc. $499.82 4

Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANESH A ALAM

NPI 1043227200 · CMS profile ID 1133215

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

WINFIELD, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043227200?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANESH A ALAM, NPI 1043227200, CMS profile ID 1133215. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043227200?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). DANESH A ALAM, NPI 1043227200, CMS profile ID 1133215. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043227200?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
DANESH A ALAM, NPI 1043227200, CMS profile ID 1133215, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1043227200?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

24 matching records · $17,495.83 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 24 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–24 of 24.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
LivaNova USA, Inc. $315.8109/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703470275 CMS
LivaNova USA, Inc. $55.0109/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703470269 CMS
LivaNova USA, Inc. $60.0009/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703470271 CMS
LivaNova USA, Inc. $69.0009/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703470273 CMS
Janssen Pharmaceuticals, Inc $3,030.0009/08/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658258027 CMS
Janssen Pharmaceuticals, Inc $1,161.2309/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658258029 CMS
Janssen Pharmaceuticals, Inc $12.9309/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658258031 CMS
Janssen Pharmaceuticals, Inc $43.1009/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658258033 CMS
Janssen Pharmaceuticals, Inc $12.9309/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658258035 CMS
Janssen Pharmaceuticals, Inc $29.4309/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658258037 CMS
Janssen Pharmaceuticals, Inc $26.9209/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658258039 CMS
Janssen Pharmaceuticals, Inc $34.9109/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658258041 CMS
US WorldMeds, LLC $125.9308/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699499741 CMS
US WorldMeds, LLC $109.6808/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699499743 CMS
US WorldMeds, LLC $38.0508/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699499745 CMS
US WorldMeds, LLC $115.4808/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699499747 CMS
US WorldMeds, LLC $7.3508/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699499749 CMS
US WorldMeds, LLC $289.0008/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699499751 CMS
US WorldMeds, LLC $50.2908/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699499753 CMS
US WorldMeds, LLC $61.2108/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699499755 CMS
US WorldMeds, LLC $18.9708/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699499757 CMS
US WorldMeds, LLC $4,200.0008/03/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699499609 CMS
US WorldMeds, LLC $128.6008/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699499611 CMS
Alkermes, Inc. $7,500.0002/11/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686569833 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $17,495.83 24
PY2020 $2,250.00 4
PY2024 $1,068.69 8
PY2025 $16,767.00 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,292.36 12
PY2025 Principal investigator $131,175.91 17
PY2024 Principal investigator $333,688.72 94
PY2023 Principal investigator $642,167.72 100
PY2022 Principal investigator $346,465.71 57
PY2021 Principal investigator $149,586.53 50
PY2020 Principal investigator $478,016.95 67
PY2019 Recipient $1,282.88 8
PY2019 Principal investigator $534,507.18 49

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

67 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alkermes, Inc. $85.00 12/31/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE, INC., BEHAVIORAL HEALTH
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 724169809
Principal investigator 1 Allergan, Inc. $8,126.84 12/31/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721316105
Principal investigator 1 Allergan, Inc. $3,533.65 12/31/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721316249
Principal investigator 1 Allergan, Inc. $12,173.30 12/15/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721312569
Principal investigator 1 Allergan, Inc. $8,754.25 12/15/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721312651
Principal investigator 1 Alkermes, Inc. $85.00 11/30/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE, INC., BEHAVIORAL HEALTH
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 724169807
Principal investigator 1 Allergan, Inc. $1,615.00 11/19/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721309119
Principal investigator 1 Allergan, Inc. $22,524.50 11/13/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721307757
Principal investigator 1 LivaNova USA, Inc. $7,500.00 11/11/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 711979275
Principal investigator 1 Alkermes, Inc. $85.00 10/31/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE, INC., BEHAVIORAL HEALTH
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 724169803
Principal investigator 1 Allergan, Inc. $3,549.20 10/16/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721303197
Principal investigator 1 Allergan, Inc. $7,805.20 10/14/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721302461
Principal investigator 1 Alkermes, Inc. $85.00 09/30/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE, INC., BEHAVIORAL HEALTH
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 724169801
Principal investigator 1 Allergan, Inc. $86.00 09/17/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721298147
Principal investigator 1 Allergan, Inc. $371.00 09/17/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721298205
Principal investigator 1 Allergan, Inc. $7,705.45 09/17/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721298363
Principal investigator 1 Allergan, Inc. $11,553.90 09/15/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721297385
Principal investigator 1 Alkermes, Inc. $85.00 09/14/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE, INC., BEHAVIORAL HEALTH
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 724169797
Principal investigator 1 Allergan, Inc. $700.00 09/01/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721294527
Principal investigator 1 Allergan, Inc. $16,013.20 08/31/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721294153
Principal investigator 1 Allergan, Inc. $371.00 08/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721292291
Principal investigator 1 Allergan, Inc. $315.00 08/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721292891
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $25,664.00 08/20/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole No dispute reported 06/30/2026 748805359
Principal investigator 1 Allergan, Inc. $12,199.90 08/12/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721289719
Principal investigator 1 Allergan, Inc. $371.00 07/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 721287529
Principal investigator 1 Allergan, Inc. $5,256.35 07/22/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721286283
Principal investigator 1 Alkermes, Inc. $85.00 07/15/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE, INC., BEHAVIORAL HEALTH
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 724177293
Principal investigator 1 Allergan, Inc. $15,634.15 07/14/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721283865
Principal investigator 1 Allergan, Inc. $315.00 07/02/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721282559
Principal investigator 1 Alkermes, Inc. $112.26 06/29/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE, INC., BEHAVIORAL HEALTH
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 724169783
Principal investigator 1 Alkermes, Inc. $77.18 06/29/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE, INC., BEHAVIORAL HEALTH
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 724169785
Principal investigator 1 Alkermes, Inc. $112.26 06/29/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE, INC., BEHAVIORAL HEALTH
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 724169789
Principal investigator 1 Alkermes, Inc. $112.26 06/29/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE, INC., BEHAVIORAL HEALTH
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 724169791
Principal investigator 1 Alkermes, Inc. $44.10 06/29/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE, INC., BEHAVIORAL HEALTH
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 724169795
Principal investigator 1 Allergan, Inc. $9,498.10 06/18/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721280823
Principal investigator 1 Allergan, Inc. $4,506.80 06/16/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721280143
Principal investigator 1 Alkermes, Inc. $85.00 06/14/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE, INC., BEHAVIORAL HEALTH
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 724177289
Principal investigator 1 Allergan, Inc. $700.00 06/04/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 721278657
Principal investigator 1 Allergan, Inc. $327.00 05/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 721276195
Principal investigator 1 Alkermes, Inc. $85.00 05/15/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE, INC., BEHAVIORAL HEALTH
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 724177279
Principal investigator 1 Alkermes, Inc. $16.00 05/15/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE, INC., BEHAVIORAL HEALTH
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 724177283
Principal investigator 1 Alkermes, Inc. $32.00 05/15/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE, INC., BEHAVIORAL HEALTH
A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness No dispute reported 06/30/2026 724177287
Principal investigator 1 Allergan, Inc. $2,942.15 05/13/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721274721
Principal investigator 1 Allergan, Inc. $315.00 05/07/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 721273791
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $74,147.00 04/23/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER No dispute reported 06/30/2026 748804643
Principal investigator 1 Allergan, Inc. $7,349.20 04/22/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721271939
Principal investigator 1 Allergan, Inc. $304.00 04/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 721271561
Principal investigator 1 Allergan, Inc. $2,997.25 04/16/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721270779
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $2,995.00 04/16/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A MULTICENTER, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WITH BIPOLAR I DISORDER No dispute reported 06/30/2026 748804517
Principal investigator 1 Allergan, Inc. $22,513.10 03/19/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721266261
Principal investigator 1 Allergan, Inc. $3,117.90 03/13/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721263831
Principal investigator 1 Allergan, Inc. $86.00 02/27/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721261135
Principal investigator 1 ACADIA Pharmaceuticals Inc $3,159.50 02/25/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
ACP-103-045 No dispute reported 06/30/2026 748381451
Principal investigator 1 Allergan, Inc. $7,745.35 02/24/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721259387
Principal investigator 1 Allergan, Inc. $300.00 02/24/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721259439
Principal investigator 1 Allergan, Inc. $650.00 02/24/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721259441
Principal investigator 1 Allergan, Inc. $1,035.00 02/24/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721259443
Principal investigator 1 Allergan, Inc. $1,050.00 02/24/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721259445
Principal investigator 1 Allergan, Inc. $1,950.00 02/24/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721259447
Principal investigator 1 Allergan, Inc. $3,136.90 02/17/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721257793
Principal investigator 1 Allergan, Inc. $700.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT OR MOST RECENT EPISODE IS MANIC No dispute reported 06/30/2026 721252065
Principal investigator 1 Allergan, Inc. $86.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721252583
Principal investigator 1 Allergan, Inc. $86.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721254189
Principal investigator 1 Allergan, Inc. $22,103.65 01/22/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721249949
Principal investigator 1 Allergan, Inc. $2,997.25 01/14/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER PATIENTS WHOSE CURRENT No dispute reported 06/30/2026 721247579
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $102,706.55 01/09/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 748803258
Principal investigator 1 Allergan, Inc. $25,188.30 01/07/2020 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721245553